Protagonist Therapeutics, Inc. (PTGX) has a MoatMap StockRank of 69/100 based on Quality (43/100), Value (35/100), and Momentum (71/100) factor scores. The current signal is BUY. Protagonist Therapeutics (Q: 32) is a biotech company with a low quality score, indicating high risk and uncertainty inherent in drug development. This type of business model does not align with the fund's philosophy of investing in established quality compounders with predictable growth and durable moats. It is too speculative for a concentrated book.
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative oral peptide therapeutics for gastrointestinal and hematology disorders. The company's competitive moat is built upon its proprietary technology platform, which enables the oral delivery of therapeutic peptides, addressing a significant challenge in drug development and potentially offering first-in-class treatments for unmet medical needs. Its focused pipeline aims to revolutionize treatment options for chronic diseases.
| Price | $102.18 |
| Market Cap | $6.3B |
| P/E (Forward) | -197.31 |
| Price/Book | 10.54 |
| Return on Equity | -17.1% |
| Return on Invested Capital | -25.4% |
| Debt/Equity | 1.49 |
| Gross Margin | 100.0% |
| Operating Margin | -6.5% |
| Revenue Growth | 99.0% |
| Free Cash Flow | $-78M |
Protagonist Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).